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Abstract
Objectives: This study compares clinico-pathological features in young (<40 years) and older patients (>50 years)
with colorectal cancer, survival in the young and the influence of pre-operative clinical and histological factors on
survival.
Materials and methods: A twelve year prospective database of colorectal cancer was analysed. Fifty-three young
patients were compared with forty seven consecutive older patients over fifty years old. An analysis of survival was
undertaken in young patients using Kaplan Meier graphs, non parametric methods, Cox’s Proportional Hazard
Ratios and Weibull Hazard models.
Results: Young patients comprised 13.4 percent of 397 with colorectal cancer. Duration of symptoms and
presentation in the young was similar to older patients (median, range; young patients; 6 months, 2 weeks to 2
years, older patients; 4 months, 4 weeks to 3 years, p > 0.05). In both groups, the majority presented without
bowel obstruction (young - 81%, older - 94%). Cancer proximal to the splenic flexure was present more in young
than in older patients. Synchronous cancers were found exclusively in the young. Mucinous tumours were seen in
16% of young and 4% of older patients (p < 0.05). Ninety four percent of young cancer deaths were within 20
months of operation. At median follow up of 50 months in the young, overall survival was 70% and disease free
survival 66%. American Joint Committee on Cancer (AJCC) stage 4 and use of pre-operative chemoradiation in
rectal cancer was associated with poor survival in the young.
Conclusion: If patients, who are less than 40 years old with colorectal cancer, survive twenty months after
operation, the prognosis improves and their survival becomes predictable.
Introduction
Colorectal cancer is the commonest malignancy in the
gastrointestinal tract and the fourth leading cause of
cancer associated death in the world. In the United
States, it has been estimated that 108,070 new cases of
colon cancer and 40,740 rectal cancers, respectively,
would have been diagnosed in 2008 and 49,960 would
have died from colorectal cancer [1]. Compared with
the West, colorectal cancer in South and South East
Asia has been reported to occur with a greater
frequency in young patients (usually <40 years old) [2],
although, in recent years, a population based study in
the United States has showna ni n c r e a s ei nt h ei n c i -
dence of colorectal cancer in the young [3].
In general, colorectal cancer is a disease of the middle
aged and elderly, with the majority diagnosed after the
age of 55 years [4]. Some 2-10% of all colorectal cancers
have been reported in young patients [4,5]. In older
patients, survival curves after operation for colorectal
cancer, as reported in most studies [6-8], assumes a
“step-ladder” form with most deaths reported in the first
three years. In young patients with colorectal cancer,
survival has been reported to be poor compared with
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any medium, provided the original work is properly cited.older patients [4] because, in the young , colorectal can-
cer is diagnosed late [9], often in advanced stage, and is
cancer with poorer differentiation [10]. Reports of survi-
val in young and older patients with colorectal cancer
tend to differ [4,9,10].
The aim of this study was to compare clinical and
pathological features of colorectal cancer in those less
than 40 years old with patients older than 50 years, and,
to specifically assess survival and factors that may influ-
ence survival in young patients having operation for col-
orectal cancer.
Materials and methods
From September 1996 to September 2008, all patients
less than 40 years old, diagnosed with colorectal cancer
and treated at the department of surgery of the univer-
sity of Kelaniya medical school, were analyzed from a
prospective database. Systematic consecutive sampling
was employed and all patients fulfilling the above
requirements were included in the study. Selected
patients’ previous medical records, discharge summaries
and histopathology reports were reviewed. Demographic
data, presenting symptoms and their duration, patholo-
gical features of the tumour, tumour localization, histo-
logical data, pre-operative carcinoembryonic antigen
(CEA) level, treatment modalities and survival data were
scrutinized. The histology report of each patient was
reviewed to determine histological subtypes [11], differ-
entiation and stage of tumour. Tumours were staged
according to the American Joint Committee on Cancer
(AJCC) TNM staging system, 6
th edition. Histological
types of tumour such as carcinoid, gastrointestinal stro-
mal and neuroendocrine tumours were excluded.
Right sided lesions were classified as tumours proxi-
mal to splenic flexure whereas left sided lesions were
classified as tumours from splenic flexure to the recto-
sigmoid junction. The rest were classified as rectal
lesions. Synchronous tumours were defined as colon
and rectal tumours detected either at pre-operative colo-
noscopy, at operation, or within 6 months of operation.
All operative specimens were evaluated by a histopathol-
ogist. On examination of the histopathology specimen,
an R0 resection refers to tumour margins which were
free of microscopic tumour and, an R1 resection, where
one or more margins of the histopathology specimen
was observed to contain microscopic tumour.
Follow up was by direct communication with patients
and their relatives in the out-patient clinic or by tele-
phone or mail. The patient or a family member was
contacted and interviewed to obtain further information.
Patients were considered lost to follow up if the patient
had failed to present at an out-patient clinic, or could
not be contacted by telephone or letter, after more than
a year. During follow up, patients were evaluated by
history and physical examination, including digital rectal
examination and CEA level every three months. A chest
radiograph and trans-abdominal ultrasound scan or
computerized tomogram was undertaken at one year.
Annual colonoscopy was performed for the first two
years and three years later, if individuals were found
free of polyps or recurrent disease. Suspicious recurrent
lesions were further evaluated with endoscopic ultra-
sound, computerized tomography, magnetic resonance
imaging and positron emission tomography if appropri-
ate. Clinical and pathological data of young patients
with colorectal cancer were compared with forty seven
patients from the same database, over 50 years old, in
whom all comparable data were available (Table 1).
Again, consecutive sampling as employed to avoid selec-
tion bias in the older age group, with the added inclu-
sion criteria being age above 50 years and presence of
complete records in all fields used for comparison.
Furthermore, in younger patients, we evaluated overall
survival after a diagnosis was made of colorectal cancer
and significant prognostic markers of survival identified
by first univariate and then multifactorial analysis. Dis-
ease free survival was analysed for all patients and also
with reference to resection margin positivity (R0/1 sta-
tus). Statistical analysis was performed using the c
2 test
or t-test as appropriate and survival probability was
Table 1 Comparison of young (n = 53) versus older (n = 47)
patients with colorectal cancer
Variable <40 years >50 years P
value
Number
(percent)
Number
(percent)
Gender
Male 26 (49%) 26 (55%) 0.53*
Female 27 (51%) 21 (45%)
Duration of symptoms
(Months)
7.9 6.6 0.44*
Neo-Adjuvant Therapy
Received 8 (15%) 11 (23.4%) 0.29*
Not received 45 (85%) 36 (76.6%)
Right hemicolectomy 6 (11%) 3 (6%)
Left hemicolectomy 3 (6%) 1 (2%)
Sigmoid colectomy 2 (4%) 4 (9%)
Anterior resection 22 (41.5%) 30 (64%)
Abdomino-perineal
resection
4 (7.5%) 5 (11%)
Subtotal colectomy 5 (9.4%) Nil
Hartmann’s procedure 3 (5.7%) 3 (6%)
Restorative
proctocolectomy
8 (15.1%) Nil
Trans-anal excision Nil 1 (2%)
*Chi square test/t-test.
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factors for survival in young patients were analysed,
using the Cox proportional hazards ratio, in univariate
and multifactorial analyses. The two issues considered
in fitting multifactorial models were whether the overall
model was adequate, and if each factor was individually
significant or redundant. This was undertaken since a
statistical method was needed that adjusts for the effect
of each factor such as R0/R1 status when assessing the
effect of other factors. Hence Type III analysis using the
Weibull Hazard model was used in factor assessment.
Adequacy of model fit was established using the log
likelihood ratio. Finally, hazard ratios were re-calculated
using the multifactorial approach for factors found sig-
nificant in type III analysis. All analyses were completed
using the SAS System V 9.00, 2003 (SAS Institute, Cary,
North Carolina, USA). P < 0.05 was considered
significant.
Results
Demography
From September 1996 to September 2008, 397 patients
were treated for colorectal cancer. Fifty-three patients
(13.4%) were young (mean age - 31.8 years; median 33
years and range -16 to 40 years). Gender ratio of young
patients was almost equal. Comparison of clinical and
pathological features in the young with older patients
with colorectal cancer (median 66 years, range -50 to 89
years) did not show a difference in gender distribution,
duration of symptoms and in the proportion of patients
with rectal cancer having pre-operative chemoradiation
(neo-adjuvant therapy) (Table 1). The median time of
follow up for the young patients was 50 months (inter-
quartile range 6 - 78 months).
Clinical Presentation
T h ed u r a t i o no fs y m p t o m sa tp r e s e n t a t i o ni ny o u n g
patients was not different from older patients (young - 2
weeks to 2 years; mean 7.9 months and median 6
months compared with older patients - 4 weeks to 3
years; mean 6.6 months and median 4 months, Student’s
t-test, p > 0.05). The longest duration for a particular
symptom was considered in determining duration of
symptoms. In the young, the most common presenting
symptom was alteration in bowel habit (47; 89%). Other
symptoms were rectal bleeding (68%), non-specific
abdominal pain (38%), tenesmus (24.5%), anaemia (6%)
and loss of appetite or weight (9%). The majority were
non-obstructing lesions with only ten patients (19%)
presenting with acute and/or sub-acute intestinal
obstruction. Likewise, in older patients, alteration in
bowel habit was the commonest symptom at presenta-
tion (41, 87%) followed by rectal bleeding (85%), tenes-
mus (26%), non-specific abdominal pain (17%), loss of
weight or appetite (17%) and anaemia (2%) respectively.
Four patients (8.5%) of the older group presented with
bowel obstruction. In most, symptoms were multiple.
Treatment
Operation was performed in all with curative intent
(Table 1). Eleven young patients (21%) had neo-adjuvant
treatment before surgery for rectal cancer and 30 (57%)
patients received post-operative adjuvant therapy overall.
In the older group, eleven (23%) with rectal cancer
received neo-adjuvant therapy and sixteen (34%)
received post-operative adjuvant therapy.
Pathological Characteristics of Tumour
The summary of tumour characteristics is shown in
Table 2. Rectal cancer comprised the majority in the
young and in older patients. In these young patients
with fifty three index cancers and four synchronous can-
cers, forty eight (84%) tumours were adenocarcinoma
without mucin, 5 (9%) were mucinous adenocarcinomas
and 4 (7%) were of the signet ring variety. The majority
of tumours were moderately differentiated. In older
patients, forty three (92%) had adenocarcinoma without
mucin, 2 (4%) had mucinous cancer and 2 (4%) had a
signet cell cancer. Most cancers in older patients were
moderately differentiated.
Of 53 young patients, pre-operative CEA was available
in 33 (mean CEA level - 20.8 ng/ml). A CEA level more
than 5 ng/ml was considered abnormal. Seventeen
patients (51.5%) had normal levels of CEA and 16
(48.5%) had abnormal pre-operative CEA levels. In older
patients, mean CEA level was 37.8 ng/ml; 34% <5 ng/ml
and 66% had a CEA level ≥5 ng/ml.
Histopathology staging of tumours in young patients
(n = 50) revealed 23 (46%) with stage I/II disease, 24
(48%) in Stage III and in the remaining 3(6%), liver
metastasis or peritoneal deposits of tumour (stage IV)
were diagnosed during operation. The majority of young
patients (40 patients; 80%) had R0 resection. In the
older age group, 55% were found to have stage I/II dis-
ease, 32% stage III and 13% with stage IV cancer. Like
in young patients, the majority of older patients (75%)
had R0 resection.
Survival Analysis in the Young
During a median fifty months of follow-up in 53 young
patients, 4 were lost to follow up early. Of the remaining
49, 16(30%) had expired. Predicted five year overall sur-
vival was 70% and disease free survival was 66% (Figures
1 and 2). Fifteen of 16 young patient deaths had
occurred within 20 months of diagnosis. Eleven had
died within the first year after surgery and 4 more in
the following year. Only one patient had died after the
second year. Fourteen (87.5%) of sixteen had died due
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tions of adjuvant therapy. In a subset analysis of AJCC
stage, 2 of 7(28.6%) with stage I cancer; 2 of 14(14.3%)
with stage II; 6 of 22(27.3%) with stage III and all stage
IV cancer patients had died. Most significantly, those
who survived longer than 20 months were likely to live
five or more years (Figure 1). In R0 patients, five-year
overall survival was 79.3% (Figure 3), while five-year dis-
ease free survival was 74.2% (Figure 4).
For overall survival, univariate analysis using Cox Pro-
portional Hazard Model revealed that AJCC stage IV, a
resection margin which was positive for tumour (i.e.R1)
and the use of neo-adjuvant chemoradiation for rectal
cancer was significantly associated with poor survival in
young patients (Table 3, Figures 3, 5,6 and 7). Of 48
young patients with rectal cancer, eleven received
neoadjuvant chemoradiation. Provision of neoadjuvant
chemoradiation seemed a significant prognostic marker
(p = 0.038, Cox proportional hazard ratio-3.01). Also, a
disease-free resection margin (R0) appeared to have sig-
nificant survival benefit compared to those with an R1
margin (Table 3). Both mucinous (5, 9.4%) and signet
ring (4, 7.5%) tumours, each, had a mortality rate of
40% and 50% respectively compared to adenocarcinoma
without mucin, 28% (p = 0.01). This was not significant
in survival analysis however. Univariate analysis of other
prognostic factors for overall survival did not show sta-
tistical significance (Table 3).
It is essential to note that both R0 and R1 patients were
included in the study. R0 tumour resection represents an
important prognostic factor for most malignant tumours.
Therefore, to avoid bias, either R0 and R1 groups would
Table 2 Comparison of clinical and pathological features in young (n = 53) versus older patients (n = 47) having
colorectal cancer
Variable <40 years ≥50 years
Gender Male 26 (51%) 26(45%)
Female 27 (49%) 21(55%)
Duration of symptoms* ≤ 3 months 22 (41.5%) 22 (47%)
>3 months 31 (58.5%) 25 (53%)
Tumour Location Right colon (included 2 synchronous lesions in <40 year group) 10 (17.5%) 3 (6%)
Left colon (included 2 synchronous lesions in <40 year group) 10 (17.5%) 13(28%)
Rectal 37 (65%) 31 (66%)
Histological types Adenocarcinoma (included 4 synchronous lesions in the young) 48 (84%) 43 (92%)
Mucinous 5 (9%) 2 (4%)
Signet ring 4 (7.0%) 2 (4%)
Tumor grade Well 10 (18.9%) 2 (4%)
Moderate 33 (62.2%) 43(92%)
Poor 10 (18.9%) 2 (4%)
T stage T0/1 5 (9.2%) 2 (4%)
T2 11 (20.4%) 9 (19%)
T3 24 (44.4%) 28 (60%)
T4 11 (20.4%) 8 (17%)
No residual tumor after chemoradiation 3 (5.6%) Nil
N stage N0 28 (51.8%) 25(54.3%)
N1 13 (24.1%) 8 (17.4%)
N2 13 (24.1%) 13 (28.3%)
AJCC staging * I 7 (14.0%) 6 (12.8%)
II 16 (32.0%) 20 (42.6%)
III 24 (48.0%) 15 (31.9%)
IV 3 (6.0%) 6 (12.8%)
Pre-operative CEA level (ng/ml) <5.0 17 (51.5%) 16 (34%)
>5.0 16 (48.5%) 31(66%)
Resection margin # R0 40 (80.0%) 35 (74.5%)
R1 10 (20.0%) 12 (25.5%)
*Data were not available in one of the older group. # Data were not available in three young patients.
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employed that adjusts for the effect of each factor such as
R0/R1 status when assessing the effect of other factors.
Thus, a Weibull Hazard model was fitted to evaluate the
significance of neoadjuvant therapy, positive resection
margins and AJCC stage 1V versus stage 1, 11 and 111.
(The lifereg procedure, SAS 9.00): the model was first
fitted using the three main effects only. Type III analysis
of effects showed neo-adjuvant therapy (p = 0.014) and
AJCC Stage IV versus stage III or less (p= 0.022) to be
significant, while a positive resection margin (p = 0.1052)
was not found to be significant. (Table 4)
When 2-way interactions between the factors were
added - first one at a time and then all three factors
Figure 1 Overall survival in young patients with colorectal cancer.
Figure 2 Disease-free survival in young patients with colorectal cancer.
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Page 5 of 11Figure 3 Involvement of the resection margin by microscopic tumour and overall survival.
Figure 4 Involvement of the resection margin by microscopic tumour and disease-free survival.
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ratio) in all cases was also not significant when com-
pared to the main effect model (Table 5). Based on
results of Table 2, 3-way interaction was not studied,
and the model with only the main effects assumed as
adequate (Table 4). Therefore it was concluded that the
two factors which were independently significant were
neo-adjuvant therapy and AJCC Stage IV vs. III or less.
Finally, multifactorial analysis using Cox Proportional
Hazard Model of these two independently significant
prognostic markers for survival in young patients was
undertaken (AJCC Stage 1V vs. AJCC stage 111 or less
and the use of neo-adjuvant therapy for rectal cancer).
Hazard Ratios were calculated for these two factors.
Both factors significantly affected survival in this model,
neoadjuvant therapy showing a Hazard Ratio of 3.390
and AJCC Stage 1V vs. stage 111 or less a ratio of 4.009
with p < 0.05 in both cases (Table 6).
Discussion
Over twelve years, fifty three of 397 (13.4%) patients
treated at our centre comprised the young colorectal
cancer group. Prevalence was comparable with most
other reports from Asia; 10.1% in Taiwan [12], Istanbul
18% [13], another Sri Lankan report of 19.7% [14], and
23% in Saudi Arabia [15]. Our figure was considerably
more than that reported from the West; 2.8% in the
United States [9], 3% in France [9] and 5.5% in New
Zealand [6,15]. The high percentage reported in devel-
oping countries may be due, in part, to the higher popu-
lation of younger people in these countries.
Young patients with colorectal cancer may be diag-
nosed late due to low suspicion of malignancy in these
patients [9]. However, the duration of presentation did
not seem to influence overall survival in this analysis
and we are in agreement with Lin et al [16]. The most
common presenting symptom was alteration of bowel
habit. Other symptoms were rectal bleeding, non-speci-
fic abdominal pain, tenesmus, anaemia, loss of appetite
and weight. The majority were not obstructive lesions.
Furthermore, in this study, the majority of young patient
cancers were sporadic with a greater frequency in the
colon compared with older patients. Synchronous can-
cers were to be found exclusively in young patients.
Hence, young patients of Asian origin, who present with
these symptoms, should be investigated without delay to
exclude malignancy.
Our study showed that a majority of young patients
had adenocarcinoma without a mucinous component
and, that about one in 5 were poorly differentiated,
which was greater than in older patients. Mucinous and
signet ring cell cancer comprised 16% of all colorectal
Table 3 Univariate analysis of prognostic factors in
young patients - Cox Proportional Hazard Model
Variable Factor
Division
n Hazard
Ratio
p
Gender Male 49 1.436 0.4751
Female
Neoadjuvant therapy Not given 48 3.012 0.0382
Given
Duration of symptoms ≤ 3 months 39 0.804 0.7472
>3 months
CEA level normal 33 1.508 0.5916
elevated
Tumour location Right colon 43 1.021 0.9586
Left colon
Rectum
Histology adenocarcinoma 46 1.237 0.7806
mucinous
Differentiation (1) Well 46 1.716 0.2131
Moderately
Poorly
Differentiation (2) Well 46 1.413 0.6510
Non-well
Differentiation (3) Poorly 46 0.451 0.1475
Non-poorly
AJCC stage (1) I 46 1.835 0.0799
II
III
IV
AJCC stage (2) I 46 1.257 0.7637
I1, 111 and 1V
AJCC stage (3) 1 and II 46 2.524 0.1134
II,111 and 1V
AJCC stage (4) 1,11 and III 46 3.925 0.0367
IV
Resection Margin R0 46 3.684 0.0142
R1
Perineural invasion - 38 2.591 0.2304
+
Lymphatic invasion - 37 2.909 0.1729
+
Vascular invasion - 38 2.404 0.1460
+
Tumor margin Pushing 13 0.817 0.8691
Infiltrating
Adjuvant therapy (1) Given 39 3.350 0.2471
Not Given
Adjuvant therapy (2) Chemotherapy 39 0.4174 0.6576
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Page 7 of 11Figure 5 AJCC stage I, II and III versus stage IV on overall survival.
Figure 6 Overall survival by AJCC stage.
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reports where mucinous, signet ring and poorly differen-
tiated tumour comprised the majority of pathology
[4,10,12,17]. One study had both mucinous and signet
ring cancer as the leading type [15]. In general, muci-
nous and signet ring tumours have been associated with
higher mortality compared with carcinoma without a
mucin component.
In the young, predicted survival at five years was 70%
and disease free survival was 66%. Our findings are in
accordance with several previous reports which also
includes a previous report by our group for survival in
older patients with colorectal cancer [8,12,13] , where
Kaplan Meier graphs for older patients have already
been displayed and discussed [8]. Unique, in this study,
is that death from cancer in those less than 40 years
occurred early, within twenty months of operation,
which is different to cancer related death reported in
those over 50 years in our previous report [8]. In other
words, those young patients who survived more than 20
months after operation were likely to live five years and
more. Our data are different to previous reports, in
which, overall five year survival rates, in young patients
with colorectal cancer, were around 30% [10,18]. Greater
five year survival in our patients may be due to the
smaller proportion of mucinous and signet ring tumours
compared with a higher prevalence of mucin producing,
high grade tumours reported in other studies.
Earlier AJCC stage and non-use of neo-adjuvant ther-
apy in patients with rectal cancer seemed to bear signifi-
cant survival benefit. The association between use of
neo-adjuvant therapy for rectal cancer and poor survival
may reflect aggressive tumour biology and later tumour
stage rather than the beneficial effect of pre-operative
chemoradiation on rectal cancer. Furthermore, although
univariate analysis showed a positive resection margin to
be associated with poor survival, The Weibull Hazard
model analysis did not find this to be a significant inde-
pendent prognostic factor. We may infer that a positive
resection margin in colorectal cancer, given that the sur-
gical procedure was performed with curative intent by a
trained surgeon, was a summative co-factor in a biologi-
cally aggressive tumour.
Figure 7 Effect of neoadjuvant therapy for rectal cancer on overall survival.
Table 4 Multifactorial analysis - Weibull Hazard Model for
Main effects
Type III Analysis of Effects Log Likelihood
Factor p
Neo-adjuvant therapy (D)* 0.0142
Resection Margin positivity (R)* 0.1052 -45.303
AJCC Stage IV vs. III or less (S)* 0.0225 *
*D, R and S are assigned symbols used to assess interaction between factors
in table Table 5
Chan et al. World Journal of Surgical Oncology 2010, 8:82
http://www.wjso.com/content/8/1/82
Page 9 of 11In our analysis, other variables such as gender, tumour
location, tumour characteristics - invasion margin
(pushing vs. infiltrative), perineural and lymphovascular
invasion - did not significantly influence overall survival.
Limitations in the current study may be attributed to a
small sample size in a single institution.
Conclusion
We found that mortality in young patients with colorec-
tal cancer was greatest in the first 20 months after
operation. Contrary to some previous reports, survival
beyond twenty months after operation in young patients
improves and is predictable.
Prognostic markers for survival were stage of disease
and the use of pre-operative chemo-radiation for rectal
cancer.
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